News
Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced Monday that it has secured the winning bid in the bankruptcy auction for key assets of 23andMe Holding Co. in a $256 million deal to boost its genetics-based drug discovery efforts.
The price tag of this acquisition suggests that the value of genetic data is declining. Back in 2018, the drug company GSK ...
To acquire Personal Genome Service, Total Health and Research Services business lines, and its Biobank and associated assets.
Me, known for its at-home DNA testing kits, is expected to be obtained by its highest bidder following a bankruptcy auction ...
Regeneron Pharmaceuticals is set to acquire substantially all assets of 23andMe for $256 million. The deal is expected to ...
Regeneron, a biotech company, will acquire 23andMe for $256 million and vowed to comply with the genetic testing company's ...
KTVU FOX 2 on MSN4d
23andMe to be acquired by NY-based Regeneron in $256 million dealThe company, which was founded in 2006, rose to prominence by offering at-home DNA testing kits that allowed people to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback